---
title: "Olema drops after hours on AstraZeneca Etcamah data"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298774579.md"
description: "Olema Pharmaceuticals shares dropped approximately 15% in after-hours trading following AstraZeneca's announcement that its SERD and CERAN candidate, Etcamah (camizestrant), failed as a first-line breast cancer treatment. Olema is developing palazestrant, another SERD/CERAN, currently in Phase 3 trials for metastatic breast cancer in collaboration with Novartis."
datetime: "2026-09-11T22:45:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298774579.md)
  - [en](https://longbridge.com/en/news/298774579.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298774579.md)
generator: "portal-rs"
---

# Olema drops after hours on AstraZeneca Etcamah data


### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [OLMA.US](https://longbridge.com/en/quote/OLMA.US.md)
- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)

## Related News & Research

- [AZN: Four oncology programmes delivered pivotal results, supporting a broad pipeline and $80bn 2030 ambition](https://longbridge.com/en/news/303125613.md)
- [Novartis Raises Guidance After Trial Setbacks Hit Profit](https://longbridge.com/en/news/303180409.md)
- [FDA Conditionally Approves AstraZeneca's Rare Kidney Disease Drug](https://longbridge.com/en/news/302758715.md)
- [AstraZeneca's Ultomiris Gets FDA Accelerated Approval As First C5 Inhibitor For IgAN](https://longbridge.com/en/news/302673006.md)
- [Novartis raises 2026 core operating income outlook to flat to low-single-digit growth](https://longbridge.com/en/news/303174362.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**